NSA/IDR Clinical Value Dossier
Physician-authored clinical evidence for Federal Independent Dispute Resolution submissions. Clinovian converts the relevant medical record into a concise, evidence-mapped narrative that the client may use in support of its independently selected offer.
A physician exception-review and overflow layer.
Built for IDR and RCM teams that already manage eligibility, coding, batching, offers, and portal submission—but need physician review when a dispute turns on patient acuity, service complexity, or resource intensity. Clinovian functions as an exception-review and overflow clinical layer, not a replacement for your existing operation.
Selective by design. Not every IDR dispute needs physician review. The service is intended for clinically differentiated, high-value, or weakly supported submissions where record-specific synthesis could materially strengthen the evidence presented.
2026 Federal IDR update. The administrative fee is $15 per party for disputes initiated on or after June 11, 2026. The operations final rule is effective August 3, 2026. Revised definitions and operational provisions have different applicability dates, and several portal-dependent changes will apply only after the Departments announce supporting functionality. Clinovian does not administer these fees or procedural steps.
High volume, tight procedure, crowded dockets.
CMS reported 1,082,247 Federal IDR payment determinations in the first half of 2025, with initiating parties — providers, facilities, and air-ambulance providers — prevailing in approximately 88% of determinations overall. Certified IDR entities are deciding disputes at enormous volume, which rewards concise, source-linked, non-duplicative clinical evidence over bulk submissions.
These are population-level figures from CMS reporting that describe the federal process as a whole. They cannot be attributed to any dossier, vendor, or evidence strategy, and they are not a Clinovian outcome claim. Whether additional clinical material affects any individual determination is decided by the certified IDR entity, not by the party’s consultant.
Strengthen the clinical reasoning inside the submission.
The QPA is a required consideration, but a certified IDR entity may also consider credible, permissible information related to the parties’ offers. Clinovian identifies the clinical facts that genuinely differentiate the encounter and maps each supported point to the underlying record.
Keep filing and strategy under the client’s control.
Clinovian is the physician-authored evidence layer behind an existing IDR, RCM, provider, or counsel workflow. We do not initiate disputes, select offers, determine eligibility, provide coding opinions, or operate the Federal IDR portal.
Not every circumstance applies in every dispute. Clinovian addresses only the circumstances supported by credible case-specific evidence and flags material information that is missing, duplicative, or outside the clinical scope.
Training, experience, quality & outcomes
Provider or facility qualifications and relevant quality or outcome measurements supported by verifiable documentation.
Market share of the parties
Client-supplied evidence regarding the provider, facility, plan, or issuer’s market position in the applicable geographic region.
Patient acuity or service complexity
Case-specific severity, comorbidity burden, resource intensity, time, risk, and clinical complexity documented in the encounter.
Teaching status, case mix & scope
Relevant facility characteristics, where applicable, connected to the circumstances of the disputed service.
Good-faith contracting history
Client-supplied evidence of network-contracting efforts and, where applicable, contracted rates between the parties during the previous four plan years.
Permissible, non-duplicative support
We avoid billed-charge, usual-and-customary, and public-payer-rate arguments, and do not relabel payment benchmarking as a statutory circumstance.
Clinical evidence map
Record citations connecting each material clinical fact to the relevant permissible consideration.
Case-specific acuity narrative
Physician-authored synthesis of severity, resource intensity, risk, time, and clinical complexity.
QPA disclosure completeness and consistency flags
Separation of the QPA, initial payment, and party offers, with missing or internally inconsistent disclosures flagged for the client.
Additional-circumstance matrix
The five categories marked supported, inapplicable, duplicative, or awaiting client documentation.
Exhibit and gap index
Supporting-document list plus missing-evidence flags before the client finalizes its submission.
Editable dossier language
Client-facing narrative that can be incorporated into the client’s own procedural and legal submission workflow.
Clinical analysis and dossier language
- Physician review of the agreed record
- Clinical-complexity and acuity synthesis
- Evidence mapping and contradiction flags
- Physician QA of analyst- or AI-drafted narratives
- Fixed scope confirmed before records are transferred
Procedural, financial and legal control
- IDR eligibility and batching decisions
- Coding validation and claim-line configuration
- Offer selection and payment valuation
- Portal credentials, initiation and submission
- Deadlines, fees, legal authorities and certifications
Clinovian will not request or accept the client’s Federal IDR portal or Gateway credentials.
Best fit
- Clinically complex emergency or post-stabilization services
- Material patient-acuity or resource-intensity differences
- High-value disputes needing physician synthesis
- Weak, generic, or AI-generated clinical narratives needing QA
- RCM and IDR teams needing a recurring physician escalation layer
Not a fit
- Portal filing, eligibility-only review, or deadline administration
- Pure coding or modifier validation
- Contract interpretation or legal briefing
- Offer valuation or market-rate opinions
- Routine disputes with no material clinical distinction
- The complete agreed record for the disputed item — the 3–5-business-day clock runs from its receipt
- The payer’s rationale and QPA disclosures, as the client is authorized to share them
- Client-supplied nonclinical circumstance evidence — market share, contracting history, teaching status — handled by the client’s authorized team
- Confirmation of the current rule and portal state from the client’s IDR administrator or counsel
- An authorized team that owns eligibility, batching, offers, deadlines, fees, and filing
- An agreed scope defining what one dossier covers — one clinically coherent narrative and evidence scope
From $750
One standard-scope Federal IDR dossier — agreed clinical narrative and evidence map. Complex or record-heavy matters quoted separately.
$1,800
One-time introductory evaluation. Three standard-scope, clinically distinct dossiers with findings discussion. Standard individual pricing begins at $2,250.
Monthly IDR Clinical QA
Monthly physician capacity for selected complex disputes, exception review, and QA of analyst- or AI-generated submissions. Custom pricing.
Federal administrative and certified-IDR-entity fees are paid and managed separately by the client and are outside Clinovian’s fee.
Standard turnaround: 3–5 business days after receipt of the complete agreed record. Expedited review by prior agreement.
What the review must resolve before a defensible handoff.
Procedural boundary
Has the client or authorized representative confirmed Federal IDR fit and retained deadlines, notices, fees, and portal work?
Clinical circumstance
Which acuity, complexity, service intensity, training, or outcome facts are actually supported?
Nonclinical circumstance
Which market, teaching, case-mix, or contracting facts must come from the client?
QPA duplication
Could a proposed circumstance merely repeat information already reflected in the QPA?
Exhibit control
Can every proposition be linked to an exhibit or identified as a gap?
What the client provides.
Scope and turnaround begin after the agreed inputs are complete enough for a responsible review. A larger record is not automatically a better record.
- Dispute and service summary after client confirms eligibility
- Relevant clinical record and disputed item or service
- QPA disclosure and payer correspondence
- Qualification, complexity, quality, or outcome evidence relied on
- Client-supplied nonclinical documents and draft submission
- Client-controlled timeline and intended dossier deadline
What the analysis is designed to prevent.
The page does not assume the adverse decision is wrong. It identifies ways a supportable case can become inaccurate, overstated, or misrouted.
- Treating the dossier as an end-to-end IDR service
- Repeating the QPA in different language
- Using generic complexity claims without record support
- Adding organizational assertions without client evidence
- Turning population IDR outcomes into a win-rate claim
How this service fits among current alternatives.
- In-house NSA/IDR operations plus clinical staff.
- Specialized managed-IDR service, such as Allia Group.
- Law firm or authorized IDR representative.
- RCM/analytics vendor handling eligibility, batching, offers, submission, and tracking.
- Direct party submission with internal clinical narrative.
- Certified IDR entities, which are neutral decision makers—not advocates or dossier vendors.
What can—and cannot—be compared.
The Federal IDR administrative fee is now $15 per party per dispute for the applicable disputes. Certified IDR entity fees are separately listed and vary by entity and dispute type; they compensate the neutral entity, not the party’s clinical consultant. (CMS certified IDR entity list) Managed-service and legal prices are generally private. These mandatory/process fees are not substitutes for Clinovian’s price.
When the service is the right instrument.
Choose it when an IDR operator already owns procedure and offer strategy but needs an organized, source-linked clinical narrative. Do not choose it when the buyer needs eligibility advice, batching, portal execution, representation, legal analysis, or a guarantee that additional clinical material will affect the determination.
Start with a de-identified IDR clinical fit assessment.
Prospective clients may submit one de-identified dispute summary. The initial assessment confirms scope, whether physician review may be useful, and the records required for a paid dossier or evaluation. No PHI is needed at this stage.